Kochi M, Fujii M, Kanamori N, Kaiga T, Okubo R, Mihara Y, Takayama T
Department of Digestive Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
J Chemother. 2011 Feb;23(1):28-31. doi: 10.1179/joc.2011.23.1.28.
The pharmacokinetics of oxaliplatin in plasma and ascitic fluid was investigated in 5 gastrointestinal cancer patients with malignant ascites. Oxaliplatin was administered at 85 mg/m² by 2-hour infusion in the FOLFOX4 regimen, and the concentrations of total and free platinum were measured. There was a trend of lower plasma C(max) values of total platinum in patients with a larger volume of ascitic fluid. The AUC(0-t) values of mean concentration curves of total plasma platinum, total ascites platinum, free plasma platinum, and free ascites platinum were 31.15, 7.96, 4.93 and 2.93 mg•h/ml, respectively. The concentrations of free ascites platinum were similar to those of free plasma platinum at the last sampling time of 26 h in each patient. The decrease or disappearance of ascitic fluid was observed in 4 patients. These results suggest that oxaliplatin exerted a beneficial effect in gastrointestinal cancer patients with malignant ascites, even when administered intravenously.
对5例伴有恶性腹水的胃肠道癌症患者研究了奥沙利铂在血浆和腹水中的药代动力学。按照FOLFOX4方案，以85mg/m²的剂量静脉输注奥沙利铂2小时，并测定总铂和游离铂的浓度。腹水体积较大的患者血浆中总铂的C(max)值有降低趋势。总血浆铂、总腹水铂、游离血浆铂和游离腹水铂平均浓度曲线的AUC(0-t)值分别为31.15、7.96、4.93和2.93mg•h/ml。在每位患者26小时的最后采样时间，游离腹水铂的浓度与游离血浆铂的浓度相似。4例患者出现腹水减少或消失。这些结果表明，即使静脉给药，奥沙利铂对伴有恶性腹水的胃肠道癌症患者也有有益作用。
